Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy

Purpose: The cytidine analogs 5-azacytidine and decitabine, used to treat myelodysplastic syndromes (MDS), produce a molecular epigenetic effect, depletion of DNA-methyltransferase 1 (DNMT1). This action is S-phase dependent. Hence, genetic factors that decrease the half-lives of these drugs could impact efficacy. Documentation of such impact, and elucidation of underlying mechanisms, could lead to improved clinical application. Experimental design: Cytidine deaminase (CDA) rapidly inactivates 5-azacytidine/decitabine. The effect of CDA SNP A79C and gender on CDA expression, enzyme activity, and drug pharmacokinetics/pharmacodynamics was examined in mice and humans, and the impact on overall survival (OS) was evaluated in 5-azacytidine/decitabine-treated patients with MDS (n = 90) and cytarabine-treated patients with acute myeloid leukemia (AML) (n = 76). Results: By high-performance liquid chromatography (HPLC), plasma CDA activity was decreased as expected in individuals with the SNP A79C. Interestingly and significantly, there was an even larger decrease in females than in males. Explaining this decrease, liver CDA expression was significantly lower in female versus male mice. As expected, decitabine plasma levels, measured by mass spectrometry, were significantly higher in females. In mathematical modeling, the detrimental impact of shorter drug half-life (e.g., in males) was greater in low compared with high S-phase fraction disease (e.g., MDS vs. AML), because in high S-phase fraction disease, even a short exposure treats a major portion of cells. Accordingly, in multivariate analysis, OS was significantly worse in male versus female patients with MDS treated with 5-azacytidine/decitabine. Conclusions: Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. Clin Cancer Res; 19(4); 938–48. ©2012 AACR.

[1]  Y. Saunthararajah,et al.  High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects , 2012, Oncotarget.

[2]  Y. Saunthararajah,et al.  Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. , 2012, Blood.

[3]  A. Jankowska,et al.  CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors , 2011, Leukemia.

[4]  O. Schmetzer,et al.  Sex differences in the drug therapy for oncologic diseases. , 2012, Handbook of experimental pharmacology.

[5]  J. Maciejewski,et al.  p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia , 2011, Leukemia.

[6]  W. Dupont,et al.  Innovative Analyses Support a Role for DNA Damage and an Aberrant Cell Cycle in Myelodysplastic Syndrome Pathogenesis , 2011, Bone marrow research.

[7]  M. Links,et al.  The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C , 2011, Asia-Pacific journal of clinical oncology.

[8]  B. Ramsahoye,et al.  Targeting of 5-aza-2′-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme , 2010, Nucleic acids research.

[9]  M. Lübbert,et al.  Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  N. André,et al.  Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Martin Dugas,et al.  Quantitative comparison of microarray experiments with published leukemia related gene expression signatures , 2009, BMC Bioinformatics.

[12]  H. Kantarjian,et al.  Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Perry,et al.  Chemical decomposition of 5-aza-2'-deoxycytidine (Decitabine): kinetic analyses and identification of products by NMR, HPLC, and mass spectrometry. , 2009, Chemical research in toxicology.

[14]  Michael Krauthammer,et al.  Integrative Analysis of Epigenetic Modulation in Melanoma Cell Response to Decitabine: Clinical Implications , 2009, PloS one.

[15]  S. Meshinchi,et al.  Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia , 2009, British journal of haematology.

[16]  J. Issa,et al.  Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines. , 2009, Blood.

[17]  M. Bernstein,et al.  Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2′-deoxycytidine , 2009, Cancer Chemotherapy and Pharmacology.

[18]  Peter A. Jones,et al.  Long-term Epigenetic Therapy with Oral Zebularine Has Minimal Side Effects and Prevents Intestinal Tumors in Mice , 2008, Cancer Prevention Research.

[19]  H. Kantarjian,et al.  A prognostic score for patients with lower risk myelodysplastic syndrome , 2008, Leukemia.

[20]  S. Salas,et al.  Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation , 2007, Pharmacogenetics and genomics.

[21]  H. Leonhardt,et al.  Dynamics of Dnmt1 interaction with the replication machinery and its role in postreplicative maintenance of DNA methylation , 2007, Nucleic acids research.

[22]  M. L. Beau,et al.  A microarray study of altered gene expression after cytarabine resistance in acute myeloid leukemia , 2007, Leukemia.

[23]  J. Issa,et al.  Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. , 2007, Blood.

[24]  Vikram Sinha,et al.  Model-Based Drug Development: The Road to Quantitative Pharmacology , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[25]  M. Grever,et al.  Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2'-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. , 2006, Rapid communications in mass spectrometry : RCM.

[26]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[27]  R. Weinshilboum,et al.  Gemcitabine Pharmacogenomics: Cytidine Deaminase and Deoxycytidylate Deaminase Gene Resequencing and Functional Genomics , 2006, Clinical Cancer Research.

[28]  M. Lübbert,et al.  Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine , 2005, Annals of Hematology.

[29]  M. Lübbert,et al.  An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients , 2005, Annals of Hematology.

[30]  H. Hori,et al.  Impact of cytidine deaminase activity on intrinsic resistance to cytarabine in carcinoma cells. , 2004, Oncology reports.

[31]  U. Dafni,et al.  A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  Y. Ravindranath,et al.  The Role of Cytidine Deaminase and GATA1 Mutations in the Increased Cytosine Arabinoside Sensitivity of Down Syndrome Myeloblasts and Leukemia Cell Lines , 2004, Cancer Research.

[33]  C. Bloomfield,et al.  Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a Cancer and Leukemia Group B study , 1995, Cancer Chemotherapy and Pharmacology.

[34]  N. Lee,et al.  Parameters for predicting allogeneic PBSCT outcome of acute myeloid leukemia: cytogenetics at presentation versus disease status at transplantation , 2004, Annals of Hematology.

[35]  L. Deangelis,et al.  Phenotypic analysis of 1-B-d-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response , 2004, Cancer Chemotherapy and Pharmacology.

[36]  W. Hiddemann,et al.  Leukaemic blasts differ from normal bone marrow mononuclear cells and CD34+ haemopoietic stem cells in their metabolism of cytosine arabinoside , 1999, British journal of haematology.

[37]  S. Seeber,et al.  Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. , 1998, Experimental hematology.

[38]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[39]  D. Budman,et al.  Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study. , 1991, Leukemia.

[40]  H. Preisler,et al.  Differences in cell cycle characteristics among patients with acute nonlymphocytic leukemia. , 1987, Blood.

[41]  D. Richards,et al.  Determination of plasma cytidine deaminase activity by HPLC. , 1987, Biomedical chromatography : BMC.

[42]  K. Kohn,et al.  Differences in DNA damage produced by incorporation of 5-aza-2'-deoxycytidine or 5,6-dihydro-5-azacytidine into DNA of mammalian cells. , 1986, Cancer research.

[43]  P. Barr,et al.  On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs , 1983, Cell.

[44]  Peter A. Jones,et al.  Cellular differentiation, cytidine analogs and DNA methylation , 1980, Cell.

[45]  J. Burchenal,et al.  Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside. , 1979, Cancer treatment reports.

[46]  R. Momparler,et al.  In vitro cytotoxic and biochemical effects of 5-aza-2'-deoxycytidine. , 1977, Cancer research.

[47]  S. Kuentzel,et al.  Enhancement by tetrahydrouridine (NSC-112907) of the oral activity of 5-azacytidine (NSC-102816) in L1210 leukemic mice. , 1975, Cancer chemotherapy reports.

[48]  C. D. Steuart,et al.  Cytidine deaminase and the development of resistance to arabinosyl cytosine. , 1971, Nature: New biology.

[49]  J. Dolan.  Eclipsing Binary Model of Cygnus XR-1 , 1971, Nature.

[50]  G. Neil,et al.  Enhancement by tetrahydrouridine of 1-beta-D-arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice. , 1970, Cancer research.

[51]  C. G. Smith,et al.  Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity. , 1967, Biochemical pharmacology.